Active	Status	Sponsor type	Region	Phase	Filter
11 Active 3 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Piperno-Neumann, Sophie
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Recruiting	2/3	420	Europe, Canada, US, RoW	IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome	IDEAYA Biosciences	Metastatic Uveal Melanoma	01/27	01/28
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Recruiting	2	82	Europe, Canada, US, RoW	Darovasertib, IDE196, LXS196	IDEAYA Biosciences	Uveal Melanoma	01/26	01/29
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer	Recruiting	2	105	Europe, Japan, US, RoW	Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide	Eli Lilly and Company	Neoplasms, Child, Adolescent	05/27	05/27
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma	Terminated	1	76	Europe, US	FHD-286	Foghorn Therapeutics Inc.	Metastatic Uveal Melanoma	11/23	11/23